At a glance
ClinicalIndex Comparison RecordN/ACompleted· 32 enrolled
Drug / intervention
Montelukast to placebo +1 moredrug
Likely dose
Montelukast to placebo 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomized, Cross-over Design Study to Compare the Lung Function Measure of Montelukast Versus Placebo in Children With Mild Persistent Asthma
In Brief
A clinical study evaluating Montelukast to placebo and Placebo to montelukast for Mild Persistent Asthma. Completed, enrolled 32 participants.
Detailed Summary
This study aims to identify markers to prove rapid improvement of lung function, airway inflammation and bronchodilator response after 2-week LTRA administration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Persistent Asthma
Countries--
CollaboratorsMerck Sharp & Dohme LLC
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 2012
Enrollment StartMay 2012
Primary CompletionSep 2015
Study CompletionDec 2015
TodayJul 2026
First PostedApr 20, 2012
Enrollment StartMay 1, 2012
Primary CompletionSep 1, 2015
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 14.2 years ago
Interventions
Montelukast to placebodrug
Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks
Placebo to montelukastdrug
Subjects will receive matching placebo. Each treatment period consists of 2 weeks